tanfanercept

Tanfanercept is a molecularly engineered recombinant fusion protein designed as a fragment of tumor necrosis factor receptor 1 (TNFR1) with high affinity for tumor necrosis factor alpha (TNF-α) and resistance to degradation by proteinases. It acts as a topical anti-inflammatory agent by selectively binding to and neutralizing TNF-α, a key cytokine mediating inflammation in dry eye disease (DED). Tanfanercept is being developed primarily for the treatment of moderate-to-severe DED and has shown statistically significant improvements in tear volume and other clinical endpoints in Phase III trials. The drug is co-developed by HanAll Biopharma and Daewoong Pharmaceutical, with additional development involvement from Harbour BioMed. Its small molecular size (~19 kDa) allows efficient ocular distribution when administered topically[1][3][4][5][6][8].

Other names

Anti-TNF-alpha proteinTNF-alpha blocker